On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
An annual review of the benefits and risks of a medicine that has been authorised under exceptional circumstances. As part of the process, the specific obligations imposed on the marketing-authorisation holder are also reviewed.
More information can be found under 'Annual re-assessment: questions and answers'.